An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Early phase 1
Where in China
- Xinhua Hospital Affiliated To Shanghai Jiao tong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT06272149
- Record updated
- 22 February 2024
- Original description
This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.Read full original descriptionShow less
An Exploratory Clinical Trial to Evaluate the Tolerability and Safety of VGN-R08b Via Intracerebroventricular Injection in Patients With Type II Gaucher Disease
This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.
Inclusion: Infants with age of ≤24 months; Historical diagnosis of Gaucher disease confirmed by GCase enzyme activity test, and with GBA1 biallelic mutations; Neurological signs and/or symptoms consistent with diagnosis of GD2; Parent(s)/legal guardian(s) of subject must give their consent for subject to enroll in the study; Parent(s)/legal guardian(s) of the subject must agree to comply with the requirements of the study, including providing disease information and support disease assessment of symptoms.
Exclusion: For those receiving enzyme replacement therapy and/or substrate reduction therapy and/or ambroxol for Gaucher disease, stable treatment ≤2 months before enrollment; Use of strong inhibitors or inducers of cytochrome CYP3A4 or P-glycoprotein (P-gp) medications, herbals, or over-the-counter agents; Any type of prior gene or cell therapy; Immunizations (live vaccines) in the prior 4 weeks; Patients with anti-AAV9 neutralizing antibody titer over 1:5; Contraindication to sedation during surgery or imaging studies (PET); Diagnosis of a significant CNS disease other than GD2 that may be a cause for the patient's GD symptoms or may confound study objectives; Clinically active infection (including HIV, HBV, HCV or syphilis); Use of systemic immunosuppressant or corticosteroid therapy other than protocol-specified (topical preparations for dermatological conditions are allowed); Presence of other significant medical conditions that would create an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study; Achieved independent gait; Severe visceral symptoms of GD which, in the opinion of the Investigator, would pose an unacceptable risk to the patient or interfere with the patient's ability to comply with study procedures or interfere with the conduct of the study; Brain MRI (magnetic resonance imaging) showing clinically significant abnormality considered to prevent intracisternal injection.